Atjaunināt sīkdatņu piekrišanu

BNF 73 (British National Formulary) March 2017 73rd Revised edition [Mīkstie vāki]

  • Formāts: Paperback / softback, 1480 pages, height x width: 210x148 mm
  • Sērija : British National Formulary
  • Izdošanas datums: 21-Mar-2017
  • Izdevniecība: Pharmaceutical Press
  • ISBN-10: 0857112767
  • ISBN-13: 9780857112767
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 90,48 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 1480 pages, height x width: 210x148 mm
  • Sērija : British National Formulary
  • Izdošanas datums: 21-Mar-2017
  • Izdevniecība: Pharmaceutical Press
  • ISBN-10: 0857112767
  • ISBN-13: 9780857112767
Citas grāmatas par šo tēmu:
Compiled with the advice of clinical experts and continually updated to reflect the latest evidence from credible sources worldwide, the new edition of the British National Formulary 73 (BNF) provides up-to-date guidance on prescribing, dispensing, and administering medicines. Access to the latest edition of the BNF is vital for healthcare professionals, as it reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.

NICE has accredited the editorial process used by the British National Formulary to produce its resources.*

New content updates in the BNF 73 include:

  • Updated guidance for conditions including anal fissure, coeliac disease, dementia, exocrine pancreatic insufficiency, food allergy, multiple sclerosis and short bowel syndrome. New prescribing guidance for biological and biosimilar medicines.
  • New drug monographs alirocumab, blinatumomab, brivaracetam, ceftobiprole, clevidipine, elvitegravir, isavuconazole, nivolumab and panobinostat.
  • New safety information about fire risk with paraffin-based skin emollients on dressings and clothing and advice on minimising the risk of infections when being treated with idelalisib.
  • Updated guidance on starting routine for oral progestogen-only contraceptives and the use of sodium glucose co-transporter 2 inhibitors as monotherapy for treating type 2 diabetes.

Improvements in the new edition:

Since the launch of the new format BNF we have actively sought your comments and feedback, and as a result have made the following improvements to this edition:

  • Important safety information is displayed prominently within the monograph
  • Class monographs (e.g. ACE inhibitors) are easy to navigate to from the individual monographs.

The BNF evaluates clinical evidence from diverse sources with information validated by a network of clinical experts and published under the authority of a Joint Formulary Committee.

Recenzijas


"The redesigned BNF remains an extensive and authoritative reference text for pharmacists and healthcare professionals.

...the indication and the dose for each drug monograph have been moved together. These two pieces of information are probably the most important for BNF users, and it is useful to be able to access this vital information quickly.

...The notes remain extensive, useful and have been simplified, with text about specific drugs being moved into the drug monographs, while text about treatment and use of drug classes remaining in the notes.

...One thing I particularly like is that all the information about the systemic use of one drug is in the same place. For example, all the uses for systemic prednisolone — asthma, chronic obstructive airways disease, ulcerative colitis, Crohn’s disease, myasthenia gravis, proctitis and so on — can all be found on the same page.

...As ever, the BNF is its own best teacher. Get to know the new structure, use it frequently and it will soon become as familiar as the previous format."

Pamela Mason, The Pharmaceutical Journal, 19 October 2015

Content of the BNF reflects current best practice as well as legal and professional guidelines relating to the uses of medicines. The resource includes:

  • Guidance on the drug management of common conditions
  • Details of medicines prescribed within the UK with special reference to their uses, cautions, contra-indications, side-effects, doses and relative costs. This allows treatment to be tailored to the individual needs of each patient.
  • Guidance on prescribing, monitoring, dispensing and adminstering medicines.

The content is updated every 6 months in print, making it an up-to-date source of prescribing advice for informed decision-making.